Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
MIR34BHG, also known as the MIR34B and MIR34C host gene, is a long non-coding RNA (lncRNA) transcribed adjacent to the microRNA miR-34b/c cluster. It is also called SPARCLE (suicidal PARP-1 cleavage enhancer). MIR34BHG/SPARCLE is induced by p53 after DNA damage and functions to enhance apoptosis by acting as a cofactor for caspase-3–mediated cleavage of PARP-1, a protein critical for DNA repair. By facilitating PARP-1 cleavage, MIR34BHG disrupts DNA-damage repair processes and promotes cell death in response to genotoxic stress. This activity is essential for effective p53-mediated tumor suppression and apoptosis. The gene is classified as a lncRNA and lacks a protein-coding function. Current data does not designate MIR34BHG as a traditional drug target or receptor, and there are no known direct interacting drugs or established clinical indications beyond its emerging role in apoptosis and potential links to cancer biology[1][2][3].
Enhances p53-induced apoptosis by promoting caspase-3–dependent PARP-1 cleavage, leading to inhibition of DNA repair and increased cell death after genotoxic stress
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on MIR34B and MIR34C host gene (MIR34BHG).